Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering

Future Microbiology
Matteo BassettiGlenn S Tillotson

Abstract

The emergence of antimicrobial resistance threatens current clinical practice across a range of infection types. Delafloxacin, a non-zwitterionic fluoroquinolone recently approved by the US FDA for the treatment of acute bacterial skin and skin structure infections, has been developed to address some of these challenges. Uniquely delafloxacin has increased intracellular penetration and enhanced antibacterial activity under acidic conditions, an environment seen in many infection sites including abscesses. Delafloxacin is active against a wide range of Gram-positive and -negative species including methicillin-resistant Staphylococcus aureus and many fluoroquinolone-resistant strains. Additionally, according to preclinical and clinical trial data, well-known adverse events related to fluoroquinolone class do not appear to occur with this new molecule. Delafloxacin has been studied in acute bacterial skin and skin structure infections with >1400 patients exposed to both intravenous and oral formulation for up to 14 days and has shown noninteriority to vancomycin with or without aztreonam. For its interesting microbiological and pharmacokinetic/pharmacodynamics characteristics and for its safety profile, delafloxacin represents a v...Continue Reading

References

Jan 1, 1987·Pharmacotherapy·R C RowenJ C Thompson
Jul 15, 1988·Annals of Internal Medicine·D J Rippelmeyer, A Synhavsky
Nov 1, 1973·Chest·R W LightP C Luchsinger
Jan 1, 1983·The American Review of Respiratory Disease·C R BodemE D Everett
Jun 1, 1995·American Journal of Respiratory and Critical Care Medicine·J E HeffnerJ M DeLeo
Oct 26, 2001·The Annals of Pharmacotherapy·J M KushnerC R Snyder
Mar 23, 2002·The Journal of Antimicrobial Chemotherapy·Ethan Rubinstein, John Camm
May 16, 2002·Pharmacotherapy·Robert C Owens, Paul G Ambrose
Apr 19, 2003·The Journal of Antimicrobial Chemotherapy·Monique I Andersson, Alasdair P MacGowan
Apr 19, 2003·The Journal of Antimicrobial Chemotherapy·A M Emmerson, A M Jones
Feb 14, 2006·Current Opinion in Pediatrics·Kathryn Edwards, David M Freeman
Jul 30, 2008·Archives of Internal Medicine·Adam L HershRalph Gonzales
Apr 20, 2011·British Journal of Clinical Pharmacology·Marie F Grill, Rama K Maganti
Nov 26, 2011·Journal of Clinical Microbiology·Marcus J ZervosMyoung Kim
Aug 10, 2012·The Journal of Antimicrobial Chemotherapy·Joan M RemyJoseph A Devito
Oct 3, 2012·The American Journal of Medicine·Barton L WiseYuqing Zhang
Dec 20, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Thamir M AlshammariKerry L LaPlante
Dec 3, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·William O'RiordanSue Cammarata
Mar 5, 2015·Journal of Medicinal Chemistry·Gregory S Bisacchi
May 20, 2015·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Andrew McEwenStuart Wood
Aug 22, 2015·BMC Infectious Diseases·Loren G MillerJose A Suaya
Aug 2, 2016·Fundamental & Clinical Pharmacology·Tina R LangJames E Gaida
Aug 30, 2016·Journal of Clinical Pharmacology·Randall HooverSue K Cammarata
Mar 31, 2017·Drug Design, Development and Therapy·Francisco Javier Candel, Marina Peñuelas
May 13, 2017·Clinical Therapeutics·Susan K PaulsonSue K Cammarata
Oct 11, 2017·Expert Opinion on Drug Metabolism & Toxicology·Matteo BassettiFederico Pea
Oct 24, 2017·Pharmacotherapy·Jonathan C ChoMarylee V Worley
Dec 9, 2017·European Journal of Medicinal Chemistry·Gui-Fu ZhangLian-Shun Feng
Dec 19, 2017·Journal of Clinical Pharmacology·Randall K HooverSue K Cammarata

❮ Previous
Next ❯

Citations

Feb 21, 2019·Expert Opinion on Pharmacotherapy·Daniele Roberto GiacobbeClaudio Viscoli
Oct 18, 2019·Expert Opinion on Pharmacotherapy·Matteo BassettiMaddalena Peghin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.